Resistance by Allostery: A Novel Perspective for Eg5-Targeted Drug Design

Authors
Viswanath, Ambily Nath InduPae, Ae Nim
Issue Date
2013-08-22
Publisher
AMER CHEMICAL SOC
Citation
JOURNAL OF MEDICINAL CHEMISTRY, v.56, no.16, pp.6314 - 6316
Abstract
Talapatra et al. elucidated the molecular basis of resistance by characterizing the binding interactions between Eg5 and the allosteric inhibitor SB743921. The investigation, employing biochemical, biophysical, and structural analyses, made path-breaking revelations in Eg5 studies and discussed a novel phenomenon "resistance by allostery", which could have far-reaching consequences from a rational drug design perspective.
Keywords
PHASE-II; INHIBITOR; PHARMACOKINETICS; CARCINOMA; ISPINESIB; SB-715992; RECURRENT; EG5; PHASE-II; INHIBITOR; PHARMACOKINETICS; CARCINOMA; ISPINESIB; SB-715992; RECURRENT; EG5; Eg5; Kinesin Spindle Protein; Allostery; anticancer
ISSN
0022-2623
URI
https://pubs.kist.re.kr/handle/201004/127761
DOI
10.1021/jm401071u
Appears in Collections:
KIST Article > 2013
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE